Krebs Biochemicals & Industries Limited

8-2-577/B, Plot No. 34, 3rd Floor, Maas Heights, Road No. 8, Banjara Hills, Hyderabad-500 034
CIN : L24110TG1991PLCO13511

May23, 2015

The Secretary
Bombay Stock Exchange Ltd.
Phiroze Jeejeebhoy Towers
27th Floor, Dalal Street
Mumbai - 400 023

Dear Sir,

Sub: Outcome of Board Meeting

At the meeting of the Board of Directors held today, the Board has decided / approved the following:

1. Audited financial results of the Company for the quarter /six months period ended 31st March, 2015. The same is enclosed along with the Auditors Report on quarterly stan alone financial results and year to date financial results pursuant to clause 41 of the listing agreement

Thanking you

Yours faithfully
For Krebs Biochemicals & Industries Limited

Avinash Ravi
Director & COO
(DIN 01616152)

Cc: The National Stock Exchange of India Ltd.
Exchange Plaza, 5th Flr, Plot # C/1
G Block, Bandra-Kurla Complex,
Bandra (E), Mumbai 400 051.

Tel : 0091-(0) 40-66037777 Fax : 0091-(0) 40-66037755
E-mail : krebs@krebsbiochem.com, marketing@krebsbiochem.com URL : www.krebsbiochem.com

STANDALONE STATEMENT OF ASSETS AND LIABILITIES AS AT 31st MARCH, 2015

Rs in Lakhs

Statement of Assets and Liabilities	As at 31.03.2015 Audited	As at 30.09.2014 Audited
I. EQUITY AND LIABILITIES		
(1) Shareholder's funds:		
(a) Share capital	951.43	951.43
(b) Share application Money	2,284.20	-
(c) Reserves and surplus	(1,407.92)	(591.24)
Sub Total - Share holders Funds	1,827.71	360.19
(2) Non-current liabilities		
(a) Long-term borrowings	5,708.71	2,231.93
(b) Long-term provisions	206.30	201.59
Sub Total - Non Current Liabilities	5,915.01	2,433.52
(4) Current liabilities		
(a) Short-term borrowings	-	347.94
(b) Trade payables	1,654.27	1,979.17
(c) Other current liabilities	1,261.43	8,467.37
(d) Short-term provisions	185.50	189.89
Sub Total - Current Liabilities	3,101.19	10,984.37
TOTAL - EQUITY AND LIABILITIES	**10,843.92**	**13,778.08**
II. ASSETS		
(1) Non-current assets		
(a) Fixed assets		
(i) Tangible assets	5,097.94	5,058.48
(il) Intangible assets under development	746.28	712.61
(b) Deferred Tax asset (Net)	131.30	131.30
(c) Long-term loans and advances	1,211.82	1,835.05
(d) Other Non-current assets	2,169.80	2,159.65
Sub Total - Non Current Assets	9,357.15	9,897.09
(2) Current assets		
(a) Inventories	545.30	3,082.44
(b) Trade receivables	37.28	61.92
(c) Cash and cash equivalents	630.94	35.61
(d) Short-term loans and advances	273.25	701.02
(e) Other current assets	-	-
Sub Total - Current Assets	1,486.78	3,880.99
TOTAL - ASSETS	**10,843.92**	**13,778.08**

Biochemicals & Industries Ltd. Hyderabad

Avinash Ravi
Director & COO
DIN: 01616152

Place : Hyderabad
Date : 23.05.2015

KREBS BIOCHEMICALS & INDUSTRIES LTD

CIN: L24110TG1991PLC013511

Regd. Office: Plot No:38, 8-2-577/B, Maas Heights, Road No:2, Banjara Hills, HYDERABAD - 500034

STAND ALONE FINANCIAL RESULTS FOR THE QUARTER / PERIOD ENDED 31ST MARCH, 2015

(Rs. In lacs)

		Quarter Ended			6 months ended	15 months ended
		31.03.2015 (Audited)	31.12.2014 (Unaudited)	31.03.2014 (Unaudited)	31.03.2015 (Audited)	30.09.2014 (Audited)
	PART - 1					
1	**Income from Operations**					
	a) Net Sales / Income from Operations (Net of Excise Duty)	-	-	-	-	-
	b) Other Operating Income	-	-	-	-	-
	Total Income from operations (net)	-	-	-	-	-
2	**Expenses**					
	a. Cost of Material Consumed	0.00	-	-	0.00	1.11
	b. Changes in inventories of finished goods, work-in-progress and stock -in-trade	-	-	-	-	-
	c. Employee benefits expense	117.74	67.94	116.41	185.68	54.64
	d. Depreciation and Amortisation expense	187.13	-	-	187.13	-
	e. Other Expenses	232.71	71.86	101.89	304.57	348.13
	Total Expenses	**537.57**	139.81	**218.30**	**677.38**	**403.88**
3	**Profit / (Loss) from Operations before other income, finanace costs and exceptional items (1 - 2)**	**(537.57)**	(139.81)	**(218.30)**	**(677.38)**	**(403.88)**
4	**Other Income**	**1.12**	-	-	1.12	17.68
5	**Profit / (Loss) from ordinary activities before finance costs (3 ± 4)**	**(536.45)**	(139.81)	**(218.30)**	**(676.26)**	**(386.20)**
6	**Finance Costs**	402.60	0.25	0.01	402.85	8.41
7	**Profit / (Loss) from Ordinary Activities before tax (5 ± 6)**	**(939.05)**	(140.06)	**(218.31)**	**(1,079.11)**	**(394.61)**
8	**Exceptional Itmes:**					
	a) Debit balances written off	**(692.16)**	-	-	**(692.16)**	-
	b) Waiver of Principal of Bank Loans & Others	**3,625.17**	-		**3,625.17**	-
	c) Diminition in Inventory	**(2,637.91)**	-		**(2,637.91)**	-
9	**Tax Expense**	-	-	-	-	**(39.99)**
10	**Net Profit / (Loss) for the period (7 ± 8)**	**(643.96)**	**(140.06)**	**(218.31)**	**(784.01)**	**(434.60)**
11	Paid-up Equity Share Capital (Face Value Rs. 10/- each)	951.43	951.43	951.43	951.43	951.43
12	Earning Per Share ((not annualised for the quarter)					
	(a) Basic	(6.77)	(1.47)	(2.29)	(8.24)	(4.57)
	(b) Diluted	(6.77)	(1.47)	(2.29)	(8.24)	(4.57)
	PART - 2					
A	**PARTICULARS OF SHAREHOLDING**					
1	**Public Share Holding**					
	- Number of Shares	67,16,146	49,16,146	47,66,146	67,16,146	49,16,146
	- Percentage of Shareholding	70.59%	51.67%	50.10%	70.59%	51.67%
2	**Promoter and Promoter Group Shareholding**					
	a) Pledged / Encumbered					
	- Number of Shares	22,08,400	42,61,724	42,61,724	22,08,400	42,61,724
	- Percentage of Shareholding (as a % of the total shareholding of promoter and promoter group)	78.92%	92.68%	89.76%	78.92%	92.68%
	- Percentage of Shares (as a % of total share capital of the Company)	23.21%	44.79%	44.79%	23.21%	44.79%
	b) Non - Pledged / Encumbered					
	- Number of Shares	5,89,740	3,36,416	4,86,416	5,89,740	3,36,416
	- Percentage of Shares (as a % of total shareholding of promoter and promoters group)	21.08%	7.32%	10.24%	21.08%	7.32%
	- Percentage of Shares (as a % of total share capital of the Company)	6.20%	3.53%	5.11%	6.20%	3.53%

	PARTICULARS	
B	**INVESTOR COMPLAINTS**	
1	PENDING AT THE BEGINNING OF THE QUARTER	NIL
2	RECEIVED DURING THE QUARTER	1
3	DISPOSED OFF DURING THE QUARTER	1
4	REMAINING UNRESOLVED AT THE END OF THE QUARTER	NIL

1. The above results have been reviewed by the Audit Committee at its meeting held on 23rd May, 2015 and approved by the Board of Directors of the Company at its meeting held on 23rd May, 2015.
2. The figures for the quarter ended 31st March 2015 are balancing figures between audited figures in respect of 6 months accounting year ended 31st March 2015 and published year to date figures for quarter ended 31st December 2014.
3. The Unit - II has started operations from April, 2015 and currently in Unit - I, the Repairs & Maintainance work is being carried on and is expected to be operational shortly .
4. Pursuant to the Companies Act 2013 becoming effective from 1st April 2014, the company has reworked depreciation with reference to the estimated useful lives of the fixed assets prescribed under schedule II to the Act. Based on transitional provision in note 7B of Schedule II, an amount of Rs.32.66 lacs has been adjusted against the retained earnings.
5. The company has not created any Diferred Tax Asset during the financial year since the company has brought forward un absorbed depreciation losses and is not expecting any taxable profits in forceable future.
6. The Company is operating in one segment only hence no segment wise results have been disclosed.
7. Figures have been regrouped wherever necessary. Figures have been rearranged wherever necessary. Also previous year figures are not comparable since they represent 15 months where as current year represent 6 months only.

Place : Hyderabad
Date : 23.05.2015

Krebs Biochemicals & Industries Hyderabad

Avinash Ravi
Director & COO
DIN: 01616152

PAVULURI & Co.
CHARTERED ACCOUNTANTS
105, 1st Block, 1st Floor, Divya Shakti Complex,
Ameerpet, Hyderabad - 500 016.
Ph : 040 - 2373 1837, 4025 8691
Fax : 040 - 2374 8729
Email : pavuluriandco@gmail.com
pavuluriandco@hotmail.com

Auditor's Report on Quarterly Stand Alone Financial Results and Year to Date Financial Results of KREBS BIOCHEMICALS & INDUSTRIES LIMITED Limited pursuant to the Clause 41 of the Listing Agreement

To,
The Board of Directors of KREBS BIOCHEMICALS & INDUSTRIES LIMITED

1. We have audited the quarterly financial results of KREBS BIOCHEMICALS & INDUSTRIES LIMITED ('the Company') for the quarter ended March 31, 2015 and the year to date financial results for the period from October 1,2014 to March 31, 2015, attached herewith, being submitted by the Company pursuant to the requirement of Clause 41 of the Listing Agreement, except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding', which have been traced from disclosures made by the Management and have not been audited by us. These quarterly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard (AS) 25, Interim Financial Reporting, specified under section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 and other accounting principles generally accepted in India.

2. We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

PAVULURI & CO. Firm Reg. No. 012194S HYDERABAD Chartered Accountants

PAVULURI & Co.
CHARTERED ACCOUNTANTS
105, 1st Block, 1st Floor, Divya Shakti Complex,
Ameerpet, Hyderabad - 500 016.
Ph : 040 - 2373 1837, 4025 8691
Fax : 040 - 2374 8729
Email : pavuluriandco@gmail.com
pavuluriandco@hotmail.com

3. Attention is invited to Note 2 of the Statement regarding figures for the quarter ended March 31, 2015 being the balancing figures between audited figures in respect of six months accounting period ended 31st March 2015 and published year to date figures for quarter ended 31st December 2014.

4. In our opinion and to the best of our information and according to the explanations given to us, these quarterly financial results as well as the year to date financial results:

   (i) are presented in accordance with the requirements of Clause 41 of the Listing Agreement in this regard: and

   (ii) give a true and fair view of the net profit and other financial information for the quarter ended March 31, 2015 as well as the year to date results for the period from October 1,2014 to March 31, 2015.

5. Further, we also report that we have, on the basis of the books of account and other records and information and explanations given to us by the management, also verified the number of shares as well as percentage of shareholdings in respect of aggregate amount of public shareholding, as furnished by the Company in terms of Clause 35 of the Listing Agreement and found the same to be correct.

For PAVULURI&Co.
Chartered Accountants
Firm Reg. No:012194S

(CA N. RAJESH)
PARTNER
M.No : 223169

Place : Hyderabad
Date : 23/05/2015